key: cord-0958561-vuoyrw8i
authors: Jesuthasan, Aaron; Massey, Flavia; Manji, Hadi; Zandi, Michael S.; Wiethoff, Sarah
title: Emerging potential mechanisms and predispositions to the neurological manifestations of COVID-19
date: 2021-08-04
journal: J Neurol Sci
DOI: 10.1016/j.jns.2021.117608
sha: c7b228d2454f3b85cd2598907298c4774d1d8a4f
doc_id: 958561
cord_uid: vuoyrw8i

A spectrum of neurological disease associated with COVID-19 is becoming increasingly apparent. However, the mechanisms behind these manifestations remain poorly understood, significantly hindering their management. The present review subsequently attempts to address the evolving molecular, cellular and systemic mechanisms of NeuroCOVID, which we have classified as the acute and long-term neurological effects of COVID-19. We place particular emphasis on cerebrovascular, demyelinating and encephalitic presentations, which have been reported. Several mechanisms are presented, especially the involvement of a “cytokine storm”. We explore the genetic and demographic factors that may predispose individuals to NeuroCOVID. The increasingly evident long-term neurological effects are also presented, including the impact of the virus on cognition, autonomic function and mental wellbeing, which represent an impending burden on already stretched healthcare services. We subsequently reinforce the need for cautious surveillance, especially for those with predisposing factors, with effective clinical phenotyping, appropriate investigation and, if possible, prompt treatment. This will be imperative to prevent downstream neurological sequelae, including those related to the long COVID phenotypes that are being increasingly recognised.

pathogen detection, effector and regulatory mechanisms or resolution of inflammation. The COVID-19 storm may therefore be similar, either relating to immune hyperactivity or a failure to resolve the initial inflammatory response as the virus is consistently replicating 1819 .

There have been previous suggestions of a cytokine storm in SARS-CoV-1 patients who demonstrated worse outcomes, which further supports this 20 . On the contrary, demonstrating the role of a cytokine storm to NeuroCOVID specifically has continued to prove difficult, although has shown success more recently. A recent study by Perrin et al.

(2021) showed that CSF samples of patients with NeuroCOVID contain elevated levels of interleukin-6 (IL-6) and hyperalbuminorrhachia, implying cytokine dysregulation and increased blood brain barrier permeability 21 NeuroCOVID possessed elevated CSF interferon-γ, chemokine and matrix metalloproteinase-10 levels 23 . However, there still remain other studies, which have been unable to replicate such findings, indicating further work is needed to validate the role of a potential cytokine storm to NeuroCOVID 24 . The brain, unlike the rest of the body, possesses its own innate immune system comprising astrocytes and microglial cells, which can recruit further inflammatory cells, such as macrophages and lymphocytes, through cytokine production 25 . In COVID-19 there appears to be over-recruitment of these inflammatory cells, which may lead to several of the described neurological sequelae 17 . This is supported by neuropathological studies, which confirm the accumulation of T cells and macrophages both in perivascular spaces, but also the brain parenchyma of NeuroCOVID patients 26, 27 . The reported expansion of dedifferentiated monocytes and exhausted T cells in the CSF of NeuroCOVID patients may J o u r n a l P r e -p r o o f Journal Pre-proof suggest many of these recruited cells are additionally ineffective to adequately control the virus 28 . Data correlating accumulations of inflammatory cells with presenting neurological symptoms however remains sparse, hence further investigation is needed to better understand this. Preclinical models suggest microglia and type 1 astrocytes are particularly responsible for the cytokine storm associated with COVID-19 25 . This is again supported by histopathological data, which show NeuroCOVID patients display activated microglia and hypertrophilic astrocytes in the cerebral perivascular spaces and brainstem 26, 27 .

Furthermore, type 1 astrocytes are shown to produce IL-1, IL-1, IL2, IL13, IL15, IL17, interferons and tumour necrosis factor in response to coronaviruses, whereas microglia induce the production of IL-6, interferons and tumour necrosis factor 29 . Young healthy adults may be able to balance this, producing a network of anti-inflammatory cytokines such as IL-4, IL-5, IL-9 and IL-10 to limit effects of the virus 30 . With ageing, this anti-inflammatory response becomes further impaired, providing a potential contributing factor to explain worse outcomes with COVID-19 in older patients.

Mitochondrial dysfunction may also be important to the pathophysiology of NeuroCOVID.

The intracellular inflammatory response triggered by the virus leads to the production of reactive oxygen species at the level of the mitochondria, further driving cytokine production and inflammation 31 . This is worsened by the limited mitochondrial release of antiviral factors, such as interferons 28 . A recent study additionally showed monocytes produced in response to COVID-19 pneumonia possess abnormal mitochondrial ultrastructure, less

The role of genetics specifically with regards to susceptibility to NeuroCOVID, however, remains unstudied. Using other viral infections as exemplars, it has been demonstrated that Herpes Simplex 1 (HSV-1) encephalitis can result from inborn mutations in the TLR3 pathway, leading to a dysregulated CNS immune response to HSV-1 45 . It may be possible that analogous genetic mechanisms are also responsible for the neuroinflammatory manifestations of COVID-19. For example, a recent study showed that individuals with lossof-function variants of the X-chromosomal TLR7 gene develop worse outcomes with the SARS-CoV-2 virus, even in young healthy patients 46 . COVID-19 susceptibility and severe disease have additionally been associated with a deficient antiviral host response and type 1 interferon signalling, although immune-related genes, such as the HLA genes, are shown not to be related 36, 43 .

Shared genes between severe COVID-19 and established neurological diseases may additionally point to shared pathogenic mechanisms, such as the OAS1 gene in Alzheimer's Disease 47 . Importantly, TMPRSS2 has also been found to be upregulated in several tissues, including the CNS, in Down's Syndrome (DS) patients, which may partly explain why these individuals appear to be more susceptible to COVID-19 infection 48 . Additionally, this may suggest DS patients would be more susceptible to neurological involvement if infected with the virus. An upregulation of IFNAR genes involved in the pro-inflammatory interferon signalling and CXCL10 gene have also been demonstrated in DS. The association between COVID-19 susceptibility and schizophrenia spectrum disorders, as well as the clinical improvement observed with aripiprazole, additionally implies there may be shared susceptibility genes between NeuroCOVID and schizophrenia 49, 50 . However, many of these aforementioned genetic associations to NeuroCOVID require further study to validate or dismiss potential links.

Journal Pre-proof

Amongst its neurological manifestations, COVID-19 has been shown to predispose patients to multiple large vessel ischaemic strokes, even in its early stages, as well as cryptogenic strokes (see Figure 4 ) 27, 51, 52 . The mechanisms underlying this remain unclear, complicated further by the confounding variable that many patients may already possess risk factors for cerebrovascular disease before becoming infected, such as hypertension, diabetes and coronary artery disease 53 . Reduced perfusion to the brain may partly be driven by systemic hypotension secondary to the cardiovascular compromise caused by COVID-19. This is supported by findings of ischaemic lesions in the borderzone areas of patients who died of the infection 54 . Other virally induced cardiovascular complications may also occur, including myocarditis, atrial fibrillation and decompensated heart failure to further increase risk of ischaemic stroke 55 . Cytokine production could additionally cause endothelial and mononuclear cell activation, with the virus also directly infecting brain endothelial cells to produce a diffuse endothelialitis and further endothelial dysfunction 56 . This would shift the vascular equilibrium towards vasoconstriction, leading to organ ischaemia and inflammation.

Downstream of this, activation of the coagulation cascade, production of thrombin and recruitment of platelets leads to thrombosis and clotting propensity 57 . Elevated antiphospholipid antibody levels found in some patients may further enhance the thrombotic risk 58 . The hypercoagulable state of COVID-19 is exemplified by elevated D-dimer levels, fibrin degradation products and increased clot strength 57 . This explains the higherthan-expected incidence of thrombotic complications elsewhere in the body, ranging from pulmonary emboli and deep vein thromboses to microangiopathies. Rarer neurovascular complications, such as cerebral venous sinus thromboses (CVST), have additionally been J o u r n a l P r e -p r o o f Journal Pre-proof described 59 . Importantly, such studies include subjects without significant inherited or acquired risk factors for developing CVST, further implying the virus directly drives hypercoagulability rather than exacerbating pre-existing risk factors for developing thromboses 60 .

Intracerebral haemorrhage has also been reported in COVID-19 patients and has been shown to be a common cause of COVID-related death, particularly in younger patients 61 . A proposed mechanism is that the virus interacts with ACE2 receptors expressed in the circumventricular organs and cerebrovascular endothelial cells 62 . As these cells usually 

The virus is also postulated to cause demyelination of the nervous system, which may be due to the cytokine storm and excessive activation of glial cells (see Figure 5) pattern has previously been attributed to a combination of hypoxia-induced tissue preconditioning and abnormally high proinflammatory cytokine levels, which may similarly explain the mechanism here 73 . The authors also found a symmetric distribution of leukoencephalopathy affecting both external capsules, which they suggested may be related to a clustering of ACE2 expression. However, ACE2 clusters have not been reported to be abundantly expressed in these regions in other studies 11 .

Reports of Guillain-Barre Syndrome (GBS) and Miller-Fisher Syndrome with the virus additionally suggested SARS-CoV-2 may utilize molecular mimicry to lead to antibodymediated destruction against cranial and peripheral nerve components 74, 75, 76 . More recently the association between COVID-19 and GBS was contradicted by a UK epidemiological study, which refuted a causal link between the two 77 . The authors conversely showed a reduced incidence of GBS during the first wave of the pandemic when compared to previous years. Lunn et al. (2020) , further suggested the increase in GBS and implied association between COVID-19 and GBS identified in the Northern Italian population was likely to be smaller than thought and could be attributed to chance rather than a causal link 75, 78 . Another study looking at hospitals in Liguria during the period of lockdown showed their total incidence of GBS cases was similar to numbers identified the year prior 79 . This was despite the risk of

A further poorly researched complication of COVID-19 is its hindrance on neurodevelopment, particularly within the paediatric population who are at greatest risk of developmental insult. A similar spectrum of NeuroCOVID is observed in children as in adults, including thrombo-ischemic disease, which follows stereotyped patterns according to acute, post-acute and post-infectious phases 86 . Brain manifestations are typically ADEM-like in presentation affecting the brain and spinal cord, particularly showing MRI signal changes in the splenium of the corpus callosum 80, 87 . In the largest paediatric NeuroCOVID study thus far, although most children had recovered upon follow-up, nine out of 38 retained mild neurological deficits, such as ataxia, limb weakness and encephalopathy 80 . A further two children had very poor outcomes, which included quadriplegia following myelitis and ventilation-dependence following anti-NMDAR encephalitis. Four children also died. It is clear that neurological deficits will prevent children from being able to acquire and develop skills at critical ages. Furthermore, patients who demonstrate a more severe profile and disease trajectory requiring longer hospital admission with persistent physical disability may experience a more significant impact on neurodevelopment 87 . With the majority of paediatric reports existing as single case studies, the effects on neurodevelopment are difficult to interpret equally across patients, warranting the need for larger longitudinal studies.

It is becoming apparent the longer-term symptoms of COVID-19 (also termed long COVID), which are largely defined as symptoms persisting beyond 4-12 weeks of their onset, are J o u r n a l P r e -p r o o f widespread in patients previously assumed to have recovered from the acute illness 88 .

Similar to acute COVID-19, long COVID is also a multisystem disorder. An Italian study reported 87% of patients discharged from hospital had ongoing symptoms after 60 days, including fatigue, cough, dyspnoea, myalgia and chest heaviness 89 . Chronic neurological symptoms, such as cognitive impairment, dysautonomia, prolonged anosmia, psychiatric disturbances including anxiety, have also been widely reported 90, 91, 92 . This extends to patients who do not require hospitalisation during the acute phase of their illness, although those with severe infection particularly requiring intensive care possess the greatest risk of suffering substantial chronic neurological and psychiatric complications 93, 94 . A UK study reported that patients with COVID-19 achieved significantly worse scores in a multi-organ assessment at 2-3 months when compared to unaffected controls 91 . The severity of chronic symptoms appears to be heterogeneous amongst patients and symptoms may additionally present in a remitting and relapsing manner 90, 95 .

The COVID Symptom Study identified several risk factors for persisting symptoms, such as obesity, female sex, age and having 5 or more listed symptoms in the first week of illness 96, 97, 98 . Coincidental illness, such as asthma and vitamin D deficiency, have been associated with persistent symptoms 97, 99 . Disease severity, hospital admission and abnormal auscultation at symptom onset also increase the risk of long COVID 100 . Moreover, 

Johns Hopkins Coronavirus Resource Center

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Multiorgan and Renal Tropism of SARS-CoV-2

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

Defining causality in COVID-19 and neurological disorders

Nervous system involvement after infection with COVID-19 and other coronaviruses

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in human and mouse brain

Elevated ACE2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication

Neuromechanisms of SARS-CoV-2: A Review

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Neurological manifestations and complications of COVID-19: A literature review

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

An interferon-γ-related cytokine storm in SARS patients

Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients

Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation. medRxiv

Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection

Microvascular Injury in the Brains of Patients with Covid-19

COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital

Neurological Manifestations of COVID-19 Feature T Cell

The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging

Mitochondria and microbiota dysfunction in COVID-19 pathogenesis

Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia

Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen

Mitochondrial oxidative phosphorylation is linked to T-cell exhaustion

The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein

Functional prediction and frequency of coding variants in human ACE2 at binding sites with SARS-CoV-2 spike protein on different populations

ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy

Genetic Risk of Severe Covid-19

Presence of Genetic Variants Among Young Men With Severe COVID-19

Genetic variability in response to amyloid beta deposition influences Alzheimer's disease risk

Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19

Association of Psychiatric Disorders With Mortality Among Patients With COVID-19

Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol

Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study

Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19

COVID-19 and cerebrovascular diseases: a comprehensive overview

Endothelial cell infection and endotheliitis in COVID-19. The Lancet

Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. Cardiovasc Drugs Ther

Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series

Early evidence of pronounced brain involvement in fatal COVID-19 outcomes

COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect

Hemorrhagic stroke and anticoagulation in COVID-19

Letter to editor: Severe brain haemorrhage and concomitant COVID-19 Infection: A neurovascular complication of COVID-19

Intracranial hemorrhage in coronavirus disease 2019 (COVID-19) patients

International Pediatric MS Study Group. Acute disseminated encephalomyelitis

Acute disseminated encephalomyelitis after SARS-CoV-2 infection

Possible Acute Disseminated Encephalomyelitis Related to Severe Acute Respiratory Syndrome Coronavirus 2

Acute Demyelinating Encephalomyelitis (ADEM) in COVID-19 Infection: A Case Series

Acute disseminated encephalomyelitis (ADEM) associated with COVID-19

Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?

Guillain-Barré Syndrome associated with SARS-CoV-2 infection

Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions

Miller Fisher Syndrome and polyneuritis cranialis in COVID-19

Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. medRxiv

COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations

COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy

Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study

Severe COVID-19-related encephalitis can respond to immunotherapy

SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses

Cerebrospinal fluid confirmed COVID-19-associated encephalitis treated successfully

SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 Encephalitis

SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability. medRxiv

Focal Cerebral Arteriopathy in a Pediatric Patient with COVID-19

Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children

Post-acute COVID-19 syndrome

Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19

Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation

Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. medRxiv

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app

Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. medRxiv

Long-term COVID-19 symptoms in a large unselected population

Report: What Does COVID-19 Recovery Actually Look Like? Patient Led Research

Follow-up of adults with noncritical COVID-19 two months after symptom onset

Association of medically unexplained fatigue with ACE insertion/deletion polymorphism in Gulf War veterans